Conic Public Biotech Fund LP has initiated a new private equity offering under Rule 506(b), a significant move that could enhance its fundraising capabilities. This development is particularly important as it reflects the growing interest in private investment opportunities within the biotech sector.

The filing, dated October 29, 2026, indicates that the fund is seeking to attract investments without disclosing specific revenue figures. The offering is designed to remain open for more than a year, with an indefinite total offering amount.

Background

Conic Public Biotech Fund LP is a limited partnership based in Atherton, California. It was incorporated in Delaware in 2026. The fund operates within the pooled investment fund sector, specifically focusing on private equity investments. Its recent filings include the current offering dated October 29, 2026, under Form D.

What the Filing Says

“The total offering amount is indefinite, with no sales reported to date.”

Impact

This offering may attract a variety of investors looking to capitalize on opportunities in the biotech industry. The filing indicates that there are no non-accredited investors involved at this time, and the fund has not yet made any sales.

What's Next

The filing does not say what happens next.

Key Personnel

The filing identifies key personnel associated with Conic Public Biotech Fund LP, including Rohan Shah and Brennan Overhoff, both serving as Executive Officers. Brennan Overhoff is noted as the Cofounder and Managing Partner, providing leadership and strategic direction for the fund.

Investment Focus

Conic Public Biotech Fund LP is classified under the pooled investment fund sector, specifically focusing on private equity investments. This strategic focus aligns with the increasing demand for innovative solutions in the biotech industry.

Offering Details

The offering will remain open for more than a year, allowing potential investors ample time to consider their participation. Notably, the filing indicates that there are no sales reported to date, and the total offering amount remains indefinite.

Financial Considerations

As part of the offering details, the fund has declined to disclose its revenue range. Additionally, there are no non-accredited investors involved in this offering, which is a common stipulation under Rule 506(b) of the SEC regulations.

Contact Information

Investors or interested parties can reach Conic Public Biotech Fund LP at their business address: 349 Selby Lane, Atherton, CA 94027. The business phone number provided in the filing is 716.341.7916.